Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)

What changed: Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)

Every dated change on the records linked to Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval2Trial result1Milestone6This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordAdvanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022MilestoneKIT
WHO and ICC classifications update advanced disease criteria
A milestone in how this cancer is treated.

2021 · 3

2017 · 2

2016 · 1

2016MilestoneMidostaurin
Midostaurin phase 2: 60 percent response rate in advanced systemic mastocytosis
A milestone in how this cancer is treated.

2007 · 1

2007MilestoneCladribine
Cladribine reported as active in advanced mastocytosis
A milestone in how this cancer is treated.

1991 · 1

1991MilestoneAdvanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Mast cell leukaemia and aggressive mastocytosis defined as distinct categories
A milestone in how this cancer is treated.